During AAN 2025, several posters comparing real-world use of Nurtec with triptans were presented. The first poster presented results from a real-world survey in patients receiving either Nurtec ...

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, ...

The portfolio of Royalty Pharma Plc (NASDAQ:RPRX) comprises royalties in more than 35 marketed drugs, such as Pfizer’s Nurtec ODT, Novartis ... its shares in 2025. Patient Capital Opportunity ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug ...

The patient and the type of organ that was transplanted have not been identified. KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty "The CDC Rabies Laboratory made the rabies confirmation. The organ donor ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical ...

Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine treatment, as well as the progression of a second drug candidate ...

By focusing on advanced diagnostic solutions and fostering cross-industry collaborations, the market is set to transform neurological care and improve patient outcomes on ... In March 2023, Biohaven’s ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. U.S. regulators are trying to shut down ...